You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAzilsartan medoxomil
Accession NumberDB08822
TypeSmall Molecule
GroupsApproved
DescriptionAzilsartan medoxomil is an angiotensin II receptor antagonist indicated for the treatment of mild to moderate essential hypertension. Azilsartan medoxomil is a prodrug of Azilsartan marketed as "Edarbi" by Takeda. Azilsartan medoxomil has so far been shown to be superior to olmesartan and valsartan in lowering blood pressure.
Structure
Thumb
Synonyms
Azilsartan
Azilsartan kamedoxomil
Azilsartan medoxomilo
Azilsartanum medoxomilum
Edarbi
External Identifiers
  • TAK-491
  • TAK-536
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EdarbiTablet40 mg/1OralTakeda Pharmaceuticals America, Inc.2011-02-25Not applicableUs
EdarbiTablet40 mgOralValeant Canada Lp/valeant Canada s.e.c.2012-11-08Not applicableCanada
EdarbiTablet80 mg/1OralTakeda Pharmaceuticals America, Inc.2011-02-25Not applicableUs
EdarbiTablet80 mgOralValeant Canada Lp/valeant Canada s.e.c.2012-11-08Not applicableCanada
EdarbiTablet40 mg/1OralArbor Pharmaceuticals2013-02-01Not applicableUs
EdarbiTablet80 mg/1OralArbor Pharmaceuticals2013-02-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
EdarbyclorTakeda Pharmaceuticals America, Inc.
SaltsNot Available
Categories
UNIILL0G25K7I2
CAS number863031-21-4
WeightAverage: 568.5336
Monoisotopic: 568.159413764
Chemical FormulaC30H24N4O8
InChI KeyQJFSABGVXDWMIW-UHFFFAOYSA-N
InChI
InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
IUPAC Name
(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 2-ethoxy-1-({4-[2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylate
SMILES
CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1
Pharmacology
IndicationTreatment of hypertension (alone or as an adjunct).
Structured Indications
PharmacodynamicsAzilsartan medoxomil decreases the pressor effect of angiotensin II. In response, angiotensin I, angiotensin II, and renin are increased while aldosterone is decreased.
Mechanism of actionAzilsartan medoxomil blocks the angiotensin II type 1 receptor preventing angiotensin II from binding and causing vasoconstriction. Azilsartan's ability to remain tightly bound to AT1 receptors for very long periods after drug washout is among its most unusual features.
TargetKindPharmacological actionActionsOrganismUniProt ID
Type-1 angiotensin II receptorProteinyes
antagonist
HumanP30556 details
Related Articles
AbsorptionAzilsartan medoxomil is hydrolyzed to the active metabolite azilsartan in the GI tract. The presence of food does not affect oral absorption of azilsartan medoxomil, and the bioavailability is 60% for azilsartan. Maximum plasma concentrations are reached in 1.5 to 3 hours.
Volume of distribution

Azilsartan medoxomil has a Vd of 16L.

Protein bindingAzilsartan medoxomil is 99% plasma protein bound.
Metabolism

Azilsartan is metabolized by CYP2C9. CYP2C9 carries out decarboxylation of azilsartan to M-I, and O-dealkylation of azilsartan to M-II. Both M-I and M-II have no pharmacologic activity.

Route of eliminationRenal clearance is 2.3 L/minute.
Half lifeThe half-life is 11 hours, and it takes about 5 days to reach steady state concentrations.
Clearance

Fecal elimination accounts for 55%, urine excretion 42%, and unchanged drug 15%.

ToxicityHypotension and diarrhea are most common.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Azilsartan medoxomil.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Acetazolamide.Approved, Vet Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Adapalene.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Azilsartan medoxomil.Approved
AliskirenAliskiren may increase the hyperkalemic activities of Azilsartan medoxomil.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Azilsartan medoxomil.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Azilsartan medoxomil.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Azilsartan medoxomil.Approved
AnisodamineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Antipyrine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Azilsartan medoxomil.Approved
ApremilastThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Apremilast.Approved, Investigational
ArdeparinArdeparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Azilsartan medoxomil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Azilsartan medoxomil.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azelastine.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Azilsartan medoxomil.Experimental
BarbitalBarbital may increase the hypotensive activities of Azilsartan medoxomil.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Barnidipine.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Azilsartan medoxomil.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benoxaprofen.Withdrawn
BepridilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Azilsartan medoxomil.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Betulinic Acid.Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Azilsartan medoxomil.Approved
BortezomibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Azilsartan medoxomil.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Azilsartan medoxomil.Approved
BromfenacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bromocriptine.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bucillamine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Azilsartan medoxomil.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Bupivacaine.Approved, Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Azilsartan medoxomil.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Carbetocin.Approved
CarprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Azilsartan medoxomil.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Azilsartan medoxomil.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Celecoxib.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Azilsartan medoxomil.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Azilsartan medoxomil.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Cilnidipine.Approved
CiprofloxacinAzilsartan medoxomil may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Azilsartan medoxomil.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Azilsartan medoxomil.Approved
ClonixinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Conivaptan.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Curcumin.Investigational
CyclosporineAzilsartan medoxomil may increase the hyperkalemic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with D-Limonene.Investigational
DalteparinDalteparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Azilsartan medoxomil.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Azilsartan medoxomil.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Desflurane.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Azilsartan medoxomil.Approved, Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Azilsartan medoxomil.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Diflunisal.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Azilsartan medoxomil.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Azilsartan medoxomil.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Azilsartan medoxomil.Approved
DrospirenoneAzilsartan medoxomil may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Droxicam.Approved
DuloxetineAzilsartan medoxomil may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ebselen.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azilsartan medoxomil.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Azilsartan medoxomil.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Azilsartan medoxomil.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etanercept.Approved, Investigational
EtodolacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Azilsartan medoxomil.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fenbufen.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fenoldopam.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fenoprofen.Approved
FimasartanThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fimasartan.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Flunixin.Vet Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Flurbiprofen.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Azilsartan medoxomil.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Azilsartan medoxomil.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Halothane.Approved, Vet Approved
HeparinHeparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved
HigenamineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Higenamine.Investigational
HMPL-004The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with HMPL-004.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Azilsartan medoxomil.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Azilsartan medoxomil.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Icatibant.Approved
IloprostThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Azilsartan medoxomil.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indoprofen.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Indoramin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azilsartan medoxomil.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Azilsartan medoxomil.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Azilsartan medoxomil.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Azilsartan medoxomil.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Azilsartan medoxomil.Approved
LacidipineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lacidipine.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Azilsartan medoxomil.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Levobupivacaine.Approved
LevodopaAzilsartan medoxomil may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Azilsartan medoxomil.Approved
LofexidineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lofexidine.Approved, Investigational
LornoxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Azilsartan medoxomil.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Loxoprofen.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Magnesium salicylate.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Azilsartan medoxomil.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Masoprocol.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Azilsartan medoxomil.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Metamizole.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Azilsartan medoxomil.Approved
MethohexitalMethohexital may increase the hypotensive activities of Azilsartan medoxomil.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Azilsartan medoxomil.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Azilsartan medoxomil.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Azilsartan medoxomil.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Azilsartan medoxomil.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Azilsartan medoxomil.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Azilsartan medoxomil.Approved
MizoribineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Moexipril.Approved
MorphineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Moxonidine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Azilsartan medoxomil.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
NafamostatThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Naftifine.Approved
NaproxenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Naproxen.Approved, Vet Approved
NCX 4016The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Azilsartan medoxomil.Approved, Investigational
NepafenacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Azilsartan medoxomil.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Azilsartan medoxomil.Approved
NicorandilNicorandil may increase the hypotensive activities of Azilsartan medoxomil.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Azilsartan medoxomil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Niflumic Acid.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Azilsartan medoxomil.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Azilsartan medoxomil.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Azilsartan medoxomil.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Azilsartan medoxomil.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azilsartan medoxomil.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olsalazine.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxaprozin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxyphenbutazone.Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Paclitaxel.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Azilsartan medoxomil.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Parecoxib.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Azilsartan medoxomil.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Phentolamine.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pimecrolimus.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Azilsartan medoxomil.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pipamperone.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Piroxicam.Approved, Investigational
PramipexoleThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Azilsartan medoxomil.Approved
PrimidonePrimidone may increase the hypotensive activities of Azilsartan medoxomil.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Propacetamol.Approved
PropofolThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Azilsartan medoxomil.Approved, Investigational
PTC299The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Azilsartan medoxomil.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Remifentanil.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Azilsartan medoxomil.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Resveratrol.Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
RiociguatThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Riociguat.Approved
RisperidoneAzilsartan medoxomil may increase the hypotensive activities of Risperidone.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sacubitril.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Salsalate.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Selegiline.Approved, Investigational, Vet Approved
SeratrodastThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Seratrodast.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Azilsartan medoxomil.Approved
SpiraprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Azilsartan medoxomil.Approved
SRT501The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Suprofen.Approved, Withdrawn
TamsulosinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azilsartan medoxomil.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Temocapril.Experimental, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Azilsartan medoxomil.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Azilsartan medoxomil.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Azilsartan medoxomil.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Thioridazine.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tiaprofenic acid.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Azilsartan medoxomil.Approved
TinoridineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Azilsartan medoxomil.Approved
TolazolineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tolmetin.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Azilsartan medoxomil.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Azilsartan medoxomil.Approved
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Azilsartan medoxomil.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Trisalicylate-choline.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Azilsartan medoxomil.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Azilsartan medoxomil.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Zomepirac.Withdrawn
Food Interactions
  • Food does not affect absorption or bioavailibity.
  • Nutrition/Herbal interaction
References
Synthesis Reference

Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T: Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem. 1996 Dec 20;39(26):5228-35.

General References
  1. Jones JD, Jackson SH, Agboton C, Martin TS: Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker. P T. 2011 Oct;36(10):634-40. [PubMed:22346296 ]
  2. Lanier G, Sankholkar K, Aronow WS: Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists. Am J Ther. 2014 Sep-Oct;21(5):419-35. doi: 10.1097/MJT.0b013e31824a0ed7. [PubMed:22975662 ]
  3. Kurtz TW, Kajiya T: Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133-43. doi: 10.2147/VHRM.S22595. Epub 2012 Feb 28. [PubMed:22399858 ]
External Links
ATC CodesC09CA09C09DA09
AHFS Codes
  • 24:32.08
PDB EntriesNot Available
FDA labelDownload (381 KB)
MSDSDownload (34.9 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.915
Caco-2 permeable-0.5843
P-glycoprotein substrateSubstrate0.5619
P-glycoprotein inhibitor INon-inhibitor0.5061
P-glycoprotein inhibitor IINon-inhibitor0.7217
Renal organic cation transporterNon-inhibitor0.8851
CYP450 2C9 substrateNon-substrate0.834
CYP450 2D6 substrateNon-substrate0.8338
CYP450 3A4 substrateSubstrate0.5128
CYP450 1A2 substrateNon-inhibitor0.7445
CYP450 2C9 inhibitorInhibitor0.5531
CYP450 2D6 inhibitorNon-inhibitor0.8779
CYP450 2C19 inhibitorInhibitor0.5915
CYP450 3A4 inhibitorInhibitor0.8507
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.594
Ames testNon AMES toxic0.5227
CarcinogenicityNon-carcinogens0.7059
BiodegradationNot ready biodegradable0.9962
Rat acute toxicity2.5320 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8853
hERG inhibition (predictor II)Non-inhibitor0.6952
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral40 mg/1
TabletOral40 mg
TabletOral80 mg/1
TabletOral80 mg
TabletOral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7157584 No2005-05-222025-05-22Us
US7572920 No2005-01-072025-01-07Us
US9066936 No2008-03-262028-03-26Us
US9169238 No2010-02-252030-02-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point212-214Not Available
water solubilitypractically insolubleNot Available
pKa6.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00703 mg/mLALOGPS
logP4.94ALOGPS
logP6.03ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)9.21ChemAxon
pKa (Strongest Basic)1.75ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area139.57 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity149.52 m3·mol-1ChemAxon
Polarizability57.73 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetracarboxylic acids and derivatives. These are carboxylic acids containing exactly four carboxyl groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassTetracarboxylic acids and derivatives
Direct ParentTetracarboxylic acids and derivatives
Alternative Parents
Substituents
  • Tetracarboxylic acid or derivatives
  • Biphenyl
  • Benzylether
  • Benzimidazole
  • Phenylmethylamine
  • Benzoyl
  • Alkyl aryl ether
  • Benzenoid
  • N-substituted imidazole
  • Carbonic acid diester
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous amide
  • Oxadiazole
  • Imidazole
  • Azole
  • 1,2,4-oxadiazole
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name:
AGTR1
Uniprot ID:
P30556
Molecular Weight:
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Miura S, Matsuo Y, Nakayama A, Tomita S, Suematsu Y, Saku K: Ability of the new AT1 receptor blocker azilsartan to block angiotensin II-induced AT1 receptor activation after wash-out. J Renin Angiotensin Aldosterone Syst. 2014 Mar;15(1):7-12. doi: 10.1177/1470320313482170. Epub 2013 Apr 5. [PubMed:23563275 ]
Comments
comments powered by Disqus
Drug created on December 21, 2012 10:01 / Updated on December 02, 2016 02:44